Amylin (1-37) Human KCNTATCATQRLANFLVHSSNNFGAILSSTNVGSNTY-acid, Disulphide bridge Cys2-Cys7
Peptide hormone deficient inpeoplewith diabetes mellitus; inhibits glucagon secretion and delays gastric emptying
Catalogue number crb1000269 Molecular Weight 3901.85 Sequence (one letter code) KCNTATCATQRLANFLVHSSNNFGAILSSTNVGSNTY-acid, Disulphide bridge Cys2-Cys7 Sequence (three letter code) H-Lys-Cys-Asn-Thr-Ala-Thr-Cys-Ala-Thr-Gln-Arg-Leu-Ala-Asn-Phe-Leu-Val-His-Ser-Ser-Asn-Asn-Phe-Gly-Ala-Ile-Leu-Ser-Ser-Thr-Asn-Val-Gly-Ser-Asn-Thr-Tyr-OH (Disulphide bridge Cys2-Cys7) Molecular Weight 3901.85 Purity >85% References
Singh et al (2015) Role of Cholesterol and Phospholipids in Amylin Misfolding, Aggregation and Etiology of Islet Amyloidosis. Adv. Exp. Med. Biol. 95 PMID: 26149927
Akter et al (2016) Islet Amyloid Polypeptide: Structure, Function, and Pathophysiology. J. Diabetes Res. 2016 1 PMID: 26649319
Amylin, also known as islet amyloid polypeptide (IAPP), is a peptide hormone which is deficient in patients with diabetes mellitus (DM). Amylin is co-secreted with insulin from the pancreatic β-cells. It inhibits glucagon secretion, delays gastric emptying, and thus acts as a satiety agent. Amylin peptide is capable of forming aggregates, and pancreatic amyloid plaques are present in 90% of patients with DM. Formation of these plaques may be inhibited by insulin via the formation of heteromolecular complexes. Amylin is also involved in adiposity signalling and body weight regulation.
Amylin is expressed in the human placenta during pregnancy where it may help regulate food intake by both the mother and foetus, and is involved in foetal development of bone, kidneys and pancreas